DNA 및 RNA 뱅킹 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 검체별, 용도별, 최종 용도별, 부문별 예측(2024-2030년)

DNA & RNA Banking Services Market Growth & Trends:

The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providing a path for the expansion of personalized medicine. Moreover, progress in translational and clinical research through an introduction of advanced, standardized cell isolation methodologies reduces hands-on-time. The development of automated solutions and the transformation of biobanks into fully automated biobanks potentially accelerate the growth of the market.

A rise in the enrollment of individuals for personalized medicine initiatives drives the revenue generation for DNA and RNA banking services. In July 2019, Partners HealthCare, U.S. enrolled more than 100,000 individuals in its precision medicine biobank that supported clinicians and researchers of the Brigham and Women's Hospital, U.S., and other partners. Such initiative assisted in examining the impact of several factors on disease and health.

The distribution network is continuously becoming complex, with pharmaceutical firms facing new challenges related to sustainability initiatives, regulatory adherence, and competing priorities cost pressures. The efforts undertaken by the key players to invest in the cold chain storage and expansion of distribution capability in various geographies have increased the capability to handle large quantities of complex cold chain biologics. Key companies such as EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex., and US Biolab have adopted several strategic alliances to reinforce their market presence.

DNA & RNA Banking Services Market Report Highlights:

• By service type, storage services accounted for the largest revenue share in 2023 owing to the presence of numerous key providers in the market space. The advent of automated sample storage systems and automated liquid handlers to manage large sample volume, and reduce the amount of time required to process, store, and distribute samples further drives the segment
• Based on specimen type, the blood segment dominated the market in 2023 owing to fast and quick procedures of collecting blood, minimal risk of contamination, and visibility of blood samples
• In terms of application, the drug discovery and clinical research segment held the largest share in 2023. Biobanking services are utilized to accelerate the discovery of new therapeutics and offer resources for future investigations to better understand the effects of environmental, genetic, and lifestyle factors on human health, morbidity, and mortality. This factor led to the maximum revenue share of the segment
• On the basis of end use, the hospitals and diagnostic centers segment is projected to witness the fastest growth throughout the forecast period owing to the efforts undertaken by government bodies and biobanks to broaden the accessibility for DNA and RNA samples in the hospitals and diagnostic centers for COVID-19 diagnosis
• North America accounted for the largest revenue share in 2023. One of the major factors positively accelerating market growth is the initiation of national precision-medicine initiatives, such as the "All of Us" biobank in the U.S.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. DNA & RNA Banking Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Industry Analysis - Porter's
  • 3.3.1. Supplier power
  • 3.3.2. Buyer power
  • 3.3.3. Substitution threat
  • 3.3.4. Threat of new entrant
  • 3.3.5. Competitive rivalry
• 3.4. PESTEL Analysis
  • 3.4.1. Political landscape
  • 3.4.2. Technological landscape
  • 3.4.3. Economic landscape

Chapter 4. DNA & RNA Banking Services Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. DNA & RNA Banking Services Market: Service Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Transportation Service
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Processing Service
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Storage Service
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Quality Control Service
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Data Storage
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA & RNA Banking Services Market: Specimen Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. DNA & RNA Banking Services Market: Specimen Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Blood
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Buccal Swabs & Hair Follicles
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA & RNA Banking Services Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. DNA & RNA Banking Services Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Therapeutics
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Drug Discovery & Clinical Research
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Diagnostics
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other Applications
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA & RNA Banking Services Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. DNA & RNA Banking Services Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
• 7.3. Academic Research
  • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Hospitals & Diagnostic Centers
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA & RNA Banking Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
• 9.4. Company Profiles
  • 9.4.1. EasyDNA
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Service benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. DNA Genotek Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Service benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. 23andMe, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Service benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. GoodCell
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Service benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. ProteoGenex
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Service benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. US Biolab Corporation, Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Service benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Infinity Biologix
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Service benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Thermo Fisher Scientific, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Service benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. deCODE genetics
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Service benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. AG Brooks Life Sciences
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Service benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. LGC Biosearch Technologies
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Service benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. PreventionGenetics
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Service benchmarking
    • 9.4.12.4. Strategic initiatives